PRESS RELEASES
Humanigen Announces Two Lenzilumab Abstracts Accepted for Presentation at 2019 Annual Meeting of American Society of Hematology

November 6, 2019

EVENTS
Next Generation CAR & T - Cell Therapies

JUN 18, 2019 • 4:30PM PDT

HIGHLIGHTS

Humanigen CEO Interview Podcast at The Wall Street Analyzer

October 28, 2019

Humanigen updates on its clinical collaboration with Gilead Sciences subsidiary, Kite

October 23, 2019

Humanigen Live Investor Presentation

October 10, 2019 (Requires free account at virtualinvestorconferences.com)

Humanigen inks licensing agreement with the University of Zurich to strengthen its treatment of graft-versus-host disease in leukemia patients

July 22, 2019

Humanigen bolsters treatment of graft-versus-host disease in leukemia patients via licensing agreement with the University of Zurich

July 22, 2019

Humanigen teams up with Kite to treat a type of lymphoma cancer

June 10, 2019

Humanigen's therapy to reduce cancer-treatment side effects highlighted in premier hematology journal

May 17, 2019

Humanigen unveils promising results from Ifabotuzumab Phase I study at the American Association for Cancer Research's annual meeting

April 1, 2019

Humanigen's new data show increase in mice survival with lenzilumab

Mzrch 28, 2019

Humanigen presents new study showing lenzilumab's potential to fight tumors

March 22, 2019

Humanigen study of monoclonal antibody in CAR-T therapy presented at Houston conference

February 25, 2019

Humanigen has gleaned 'significant' interest from potential partners from its data presentation

February 11, 2019

Humanigen new research shows encouraging results for cancer treatment using Car-T

December 5, 2018

Humanigen CEO says company is developing drug to make 'the new frontier' in cancer therapy safer

June 9, 2018

Humanigen CEO Speaks with OTC Markets About Strategy to Optimize Car-T Therapy

Cure Brain Cancer Foundation (Australia) Highlights Ifabotuzumab Clinical Trial for GBM

March 1, 2018

Immunotherapy: The Promise and Perils of a New Generation of Cancer Treatments (Stat eBook)

Spring 2017

Axicabtagene Ciloleucel CAR T-Cell Therapy Paper Notes GM-CSF as Biomarker Significantly Associated with Neurotoxicity

December 28, 2017

Cancer Researchers Learn More About Toxic Side Effects of New Treatments

October 12, 2017

Editorial in Blood Journal

by Omar Ahmed

CAR-T–cell neurotoxicity: hope is on the horizon

©2019 Humanigen, Inc.  All rights reserved